Affiliate disclosure: This article contains affiliate links. If you buy through them, we may earn a commission at no extra cost to you. This does not influence our assessment of the evidence below.
Evidence rating: Preliminary, with a major caveat — alpha-GPC has meta-analytic cognitive support, but the tinnitus claim is contradicted by two Cochrane reviews of the lead ingredient
What NeuroQuiet Claims To Be
NeuroQuiet is an oral spray marketed to adults roughly 30 to 70, promising hearing support, tinnitus relief, and sharper mental clarity. It combines three pitches into one bottle: quiet the ringing, protect the ears, sharpen the mind.
Those three claims do not rest on equal footing, and the difference matters enough that it drives this entire review. One of them has decent evidence. One has almost none. And one has been tested repeatedly and come up empty.
What’s Actually In It
The published ingredient list names ten components:
- Alpha-GPC (choline alphoscerate)
- Ginkgo biloba
- GABA
- L-dopa bean (Mucuna pruriens)
- L-tyrosine
- L-arginine
- Grape seed extract
- Green tea extract
- Moomiyo (shilajit)
- Vitamin B12
No amounts are disclosed for any of them. In a spray format that is a bigger problem than usual — total delivered volume per dose is small, and ten ingredients splitting a few sprays leaves little room for any of them to reach a studied dose.
What The Research Shows
According to PubMed, the evidence here splits cleanly along the product’s three claims.
Ginkgo does not appear to help tinnitus. This is the central finding and it is not a close call. A 2022 Cochrane systematic review pooled 12 randomized controlled trials covering 1,915 participants. On tinnitus symptom severity measured by the Tinnitus Handicap Inventory, ginkgo showed a mean difference of -1.35 points on a 100-point scale versus placebo — clinically meaningless, and the evidence graded very low certainty. No benefit was found for tinnitus loudness or health-related quality of life either. DOI
An earlier Cochrane review reached the same conclusion. Four trials, 1,543 participants, all assessed as low risk of bias. The verdict: “There was no evidence that Ginkgo biloba was effective in patients with a primary complaint of tinnitus.” A small reduction did appear in dementia patients who happened to have mild tinnitus, but their baseline tinnitus scores were only 1.7 to 2.5 out of 10, and the authors called the practical clinical significance unclear. DOI
Ginkgo’s cognitive record is also weaker than commonly believed. A Cochrane review of ginkgo for dementia and cognitive impairment found some benefit on clinical global improvement at 24 weeks with doses above 200 mg/day, and on cognition at 12 weeks — but not at 24 weeks, and not consistently across doses. The authors’ bottom line: the evidence for “predictable and clinically significant benefit” is “inconsistent and unconvincing.” Ginkgo was, however, safe, with no excess adverse events over placebo. DOI
Alpha-GPC is the ingredient that actually delivers. A systematic review and meta-analysis screened 1,326 studies and included seven RCTs plus a prospective cohort. Choline alphoscerate significantly improved cognition (mean difference 1.72), functional outcomes (0.79), and behavioral outcomes (-7.61) in adults with cognitive impairment tied to cerebrovascular injury, and patients receiving alpha-GPC scored significantly better on cognition than those given placebo or other medications. This is real, pooled, randomized evidence — for cognition, not for hearing. DOI
The Honest Verdict
What holds up: Alpha-GPC. It has a genuine meta-analysis behind it for cognitive and functional outcomes, and it is the strongest thing in this bottle by a wide margin. L-tyrosine has reasonable support as a catecholamine precursor under stress, and B12 deficiency is a real cause of neurological symptoms worth correcting. Ginkgo is at least safe — the Cochrane data are clear that it does not cause harm.
What doesn’t: The tinnitus claim, which is the product’s headline. Two independent Cochrane reviews spanning roughly 3,400 participants across sixteen trials found ginkgo does not reduce tinnitus when tinnitus is the primary complaint. That is not absence of evidence; it is evidence of absence, and it is the best-quality evidence available on any ingredient in this formula. The hearing-protection claim has no comparable trial support at all — antioxidant and blood-flow reasoning about the inner ear is mechanism, not outcome data. GABA taken orally also crosses the blood-brain barrier poorly, which undercuts the “inner ear cell protection” rationale. And with no disclosed doses, there is no way to know if the alpha-GPC — the one ingredient that earned its place — is present at anything near a studied amount.
Who this makes sense for: Someone primarily interested in the cognitive ingredients, who reads the tinnitus marketing as marketing and buys it for alpha-GPC and tyrosine with modest expectations. Even then, a single-ingredient alpha-GPC product at a disclosed dose would be the more rational purchase.
Who should skip it: Anyone buying this specifically for tinnitus relief. The evidence does not support that claim, and tinnitus that is new, one-sided, pulsatile, or accompanied by hearing loss needs an ENT evaluation, not a spray. Also skip if you take blood thinners — ginkgo has antiplatelet activity — or if you take MAO inhibitors or levodopa, since the L-dopa bean can interact meaningfully with both.
Check current pricing and availability
View NeuroQuiet on the official site
This article is for informational purposes only and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Talk to your physician or an audiologist before starting any supplement, especially if you have a diagnosed condition or take medication.
Research cited via PubMed:
- Sereda M, et al. Cochrane Database Syst Rev. 2022;11(11):CD013514. DOI
- Hilton MP, Zimmermann EF, Hunt WT. Cochrane Database Syst Rev. 2013;2013(3):CD003852. DOI
- Birks J, Grimley Evans J. Cochrane Database Syst Rev. 2007;(2):CD003120. DOI
- Sagaro GG, Traini E, Amenta F. J Alzheimers Dis. 2023;92(1):59-70. DOI